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Background: Obesity and the related entity metabolic syndrome are characterized by altered lipid meta-
bolism and associated with increased morbidity risk for cardiovascular disease and cancer. Oxysterols
belong to a large family of cholesterol-derived molecules known to play crucial role in many signaling
pathways underlying several diseases. Little is known on the potential effect of obesity and metabolic
syndrome on oxysterols in human.
Objectives: In this work, we questioned whether circulating oxysterols might be significantly altered in
obese patients and in patients with metabolic syndrome. We also tested the potential correlation
between circulating oxysterols and fatty acids.
Methods: 60 obese patients and 75 patients with metabolic syndrome were enrolled in the study along
with 210 age- and sex-matched healthy subjects, used as control group. Plasma oxysterols were analyzed
by isotope dilution GC/MS, and plasma fatty acids profiling was assessed by gas chromatography coupled
with flame ionization detection.
Results: We found considerable differences in oxysterols profiling in the two disease groups that were
gender-related. Compared to controls, males showed significant differences only in 4a- and 4b-hydrox-
ycholesterol levels in obese and metabolic syndrome patients. In contrast, females showed consistent dif-
ferences in 7-oxocholesterol, 4a-hydroxycholesterol, 25-hydroxycholesterol and triol. Concerning fatty
acids, we found minor differences in the levels of these variables in males of the three groups.
Significant changes were observed in plasma fatty acid profile of female patients with obesity or meta-
bolic syndrome. We found significant correlations between various oxysterols and fatty acids. In partic-
ular, 4b-hydroxycholesterol, which is reduced in obesity and metabolic syndrome, correlated with a
number of saturated and mono-unsaturated fatty acids that are end-products of de novo lipogenesis.
Conclusions: Our data provide the first evidence that obesity and metabolic syndrome are associated with
major, gender-specific, changes in circulating oxysterols and fatty acids. These findings suggest a meta-
bolic link between oxysterols and fatty acids, and that oxysterols may contribute to the epidemic diseases
associated with obesity and metabolic syndrome in female.
 2015 Elsevier Inc. All rights reserved.1. Introduction important complications, including the metabolic syndrome, thatObesity is a medical condition characterized by excessive accu-
mulation of fat in the body and is better defined as a body mass
index of 30 and above. It is a major epidemic and a public health
concern worldwide [1]. Some obese patients may developfavor premature death [2]. Metabolic syndrome is the most studied
complication in obesity and is diagnosed by the co-occurrence of
three out of five of the following conditions: abdominal (central)
obesity, high blood pressure, high fasting plasma glucose, high
serum triglycerides, and low high-density cholesterol (HDL) levels
[3]. Additional complications such as liver disorders (non alcoholic
fatty liver diseases) [4], inflammatory bowel diseases [5],
reproductive disorders including infertility [6], autoimmune dis-
eases [7] and many cancers [8] may also develop in obesity.
Interestingly, preclinical and clinical studies have provided
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associated with obesity.
Oxysterols are a complex family of oxidized species of choles-
terol [9]. They are powerful bioactive lipids able to influence an
array of biological processes [10] and may be involved in the
pathologies associated with obesity. There are several mechanisms
by which oxysterols influence cell signaling and physiology.
Oxysterols are potent regulators of cholesterogenic pathways
[11] and they act as ligands for receptors such as the Liver X
Receptors (LXRs) [12], which are nuclear receptors that act as oxys-
terol sensors and regulate gene expression [13]. They are highly
expressed in the liver where they regulate the expression of genes
involved in cholesterol and fatty acid metabolism [14]. More
recently, it has also been shown that 27-hydroxycholesterol act
as selective estrogen receptor modulators (SERM) [15] and influ-
ence the cardiovascular system, bone biology and cancer [16].
There are little data on the relationship between oxysterol and
metabolic diseases in human. In this work we investigated
whether obesity and metabolic syndrome might have a significant
impact on serum oxysterol profile. Because cholesterol metabolism
shows important gender specificity and oxysterols act as SERMs
we questioned this both in males and in females. In addition, var-
ious independent works provided evidence that not only fatty acid
metabolism is regulated by oxysterol receptors (LXRs) [14,17] but
also that fatty acids influence LXR activity [18,19]. Therefore, we
tested whether changes in oxysterol concentrations may be corre-
lated to changes in circulating fatty acids.
2. Methods
2.1. Study population and design
To investigate the characteristics of plasma FA and oxysterols
pattern in patients with obesity and metabolic syndrome we con-
secutively recruited 142 subjects at Sapienza University outpatient
centers for Obesity and Vascular Medicine (obesity patients, n = 67;
MS, n = 75) between January 2009 and July 2011. Inclusion criteria
for obese patients were based on BMI > 30 in the absence of dys-
lipidemia, diabetes or hypertension. Diagnosis of metabolic syn-
drome was based on the ATPIII criteria [3]. Exclusion criteria
included, previous angina, myocardial infarction, TIA or stroke,
familial dyslipidemias, thyroid disease, kidney disease, systemic
inflammatory diseases or cancer.
Healthy controls (n = 210), matched for age and sex, were
recruited in the same geographical area, after carefully reviewing
their medical history, among blood donors referring to the AVIS
center of Latina. Healthy subject definition was based on the
absence of any known clinical or anamnestic disease, and the
absence of cardiovascular risk factors apart from smoking.
The study procedure was developed according to the guidelines
of the Ethic Committee, which approved the protocol, and the
Helsinki Declaration of 1975. All subjects signed written informed
consent.
2.2. Plasma biochemistry
Serum glucose, bilirubin, uric acid, alanine transaminase, choles-
terol, triglycerides, HDL-and cholesterol were determined by
standard automated techniques as previously described [20].
Laboratory analyseswere done in a blinded fashion. The clinical pic-
ture of the patients referred to in this study is described in Table 1.
2.3. Lipid biochemistry
To measure plasma FAs, peripheral venous blood was obtained
after overnight fasting and was centrifuged at 4 C. Plasma wasthen removed and stored at 80 C until assay. Before analysis
FAs were processed for direct transesterification with acetyl chlo-
ride according to a previously published method [21]. Analyses
were performed on an Agilent 7820A Plus Gas Chromatograph
(Agilent Technologies; Palo Alto, CA) equipped with a G4513A
automatic liquid sampler and a flame ionization detector.
Separation was carried out on a 100 m capillary column (Supelco,
SP-2560 100 m  0.25 mm ID, 0.20 lm thickness) (Sigma Aldrich,
Milan, Italy). Identification, precision, and accuracy were evaluated
using mixtures of authentic methylated FA standards, and a control
plasma pool as previously described [22,23]. The list of FAs species
that were analysed is reported in Supplementary Table 1.
Oxysterols were determined by GC–MS using deuterium-
labelled internal standards, as previously described [24]. Prior to
analysis the isolated oxysterol fraction was submitted to base
hydrolysis, hence the concentrations measured are for total
oxysterols comprising the sum of esterified and non-esterified
molecules. 5a-OH,6-oxocholesterol, d6-5a-OH,6-oxocholesterol,
cholestane, triol and d6-triol were synthesized and kindly donated
by Dr. Marc Poirot (Institut Claudius Régaud, Toulouse, France).
4a- and 4bOH-Cholesterol were kindly donated by Dr. G. Lizard
(Faculté des Sciences Gabriel, Dijon, France). All other oxysterols
and deuterated oxysterols were from Avanti Polar Lipids. The list
of oxysterols measured here is reported in Supplementary Table 2.
2.4. Statistical analysis
Kruskal–Wallis test was used to compare oxysterol and fatty
acid concentrations between the three health status groups
(healthy, obesity, metabolic syndrome). This is a non-parametric
univariate test that treats each variable independently. Multiple
testing corrections (adjusted p-values), the false discovery rate,
were applied to avoid false positive [25].
A heatmap was used to represent relationships between fatty
acids and oxysterols. This is a graphical representation of Kendall
correlation coefficients using darker colors to indicate high correla-
tions, and brighter colors to indicate low correlations. Statistical
analysis was performed using R software (http://www.r-project.
org/).3. Results
3.1. Clinical characteristics of the study population
Based on the ATPIII criteria, participants were classified as
healthy controls, metabolic syndrome or obesity patients. We used
these groups to investigate the respective influence of obesity and
metabolic syndrome on plasma oxysterols and fatty acids.
Demographic and clinical characteristics of the study population
are shown in Table 1. Oxysterol profile showed significant differ-
ences in the three groups (Supplementary Table 3). However, anal-
ysis performed independently in patients from each gender
revealed that these changes were markedly gender-dependent.
3.2. Influence of obesity and metabolic syndrome on plasma oxysterol
concentration in males
Interestingly, we found that obesity alone has little impact on
plasma oxysterols concentration when compared to healthy
controls (Table 2). Only 4b-hydroxycholesterol and 4a-hydroxyc-
holesterol were significantly different in males. Both 4b-hydroxyc-
holesterol and 4a-hydroxycholesterol were lower in obese
patients compared to healthy subjects. In patients with metabolic
syndrome the level of 4b-hydroxycholesterol was lower and the
level of and 4a-hydroxycholesterol was higher compared to healthy
Table 1
Demographic and clinical characteristics of the study population.
HC
(n = 210)
OB
(n = 67)
MS
(n = 75)
ANOVA HC vs. OB HC vs. MS MS vs. OB
F p
Age (years) 41.7 ± 11.4 40.5 ± 12.2 45.9 ± 10.1 4.8 0.008 n.s. 0.02 0.016
BMI (kg/m2) 25.3 ± 2.4 34.9 ± 4.7 35.1 ± 6.0 251.8 <0.0001 <0.0001 <0.0001 n.s.
Male sex (%) 136 (64) 28 (41) 41 (54)
SBP (mmHg) 120 ± 12 120 ± 12 135 ± 14 38.7 <0.0001 n.s. <0.0001 <0.0001
DBP (mmHg) 78 ± 8 78 ± 9 87 ± 9 35.5 <0.0001 n.s. <0.0001 <0.0001
TC (mg/dL)* 198.89 ± 37.53 184.97 ± 37.79 210.27 ± 42.97 7.5 0.001 0.01 0,03 <0.0001
HDL-c (mg/dL)* 57.6 ± 13.5 49.9 ± 10.4 46.8 ± 11.3 24.8 <0.0001 <0.0001 <0.0001 n.s.
TG (mg/dL)* 86.09 ± 36.87 93.09 ± 38.91 143.43 ± 69.48 43.6 <0.0001 n.s. <0.0001 <0.0001
HC, healthy controls; MS, metabolic syndrome; OB, obesity; BMI, body max index; SBP, sistolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; HDL-c, high
density lipoprotein-cholesterol; TG, triglycerides; n.s., not significant. Values are expressed as mean ± SD; LSD was used for post hoc comparison between groups.
* To convert TC and HDL-c values in mmol/L divide by 38.67; to convert TG values in mmol/L divide by 88.57.
Table 2
Concentration of serum cholesterol and oxysterols measured in males by health status.
HC OB MS p1 HC/OB HC/
MS
OB/
MS
TC (mg/dL) 199.23 ± 39.02 201.95 ± 29.41 209.57 ± 41.78 0.1978 n.s. n.s. n.s.
4bOH-CH 17.77 ± 5.22 13.33 ± 2.80 16.16 ± 5.49 0.0019 0.0083 0.0186 n.s.
4bOH-CH/TC 9.06 ± 2.54 6.71 ± 1.65 7.84 ± 2.52 0.0001 0.0004 0.0004 n.s.
5aOH,6oxo-CH 1.30 ± 0.32 1.49 ± 0.55 1.43 ± 0.44 0.1330 n.s. n.s. n.s.
5aOH,6oxo-CH/TC 0.67 ± 0.21 0.75 ± 0.30 0.70 ± 0.23 0.8472 n.s. n.s. n.s.
5,6a-epoxy 11.13 ± 9.55 9.55 ± 3.10 10.45 ± 3.39 0.3347 n.s. n.s. n.s.
5,6a-epoxy/TC 5.69 ± 4.29 4.78 ± 1.65 5.1 ± 1.75 0.8472 n.s. n.s. n.s.
5,6b-epoxy 20.62 ± 10.78 19.00 ± 6.59 21.28 ± 8.15 0.3347 n.s. n.s. n.s.
5,6b-epoxy/TC 10.65 ± 5.44 9.43 ± 3.04 10.42 ± 4.51 0.8472 n.s. n.s. n.s.
27OH-CH 59.66 ± 15.12 58.28 ± 12.67 63.06 ± 18.32 0.3347 n.s. n.s. n.s.
27OH-CH/TC 30.77 ± 8.68 19.12 ± 6.66 30.77 ± 8.74 0.8472 n.s. n.s. n.s.
7aOH-CH 36.03 ± 23.96 40.79 ± 27.35 43.96 ± 24.79 0.1330 n.s. n.s. n.s.
7aOH-CH/TC 17.10 ± 10.97 20.24 ± 13.37 21.24 ± 12.09 0.6313 n.s. n.s. n.s.
Triol 2.74 ± 0.80 2.54 ± 0.88 2.99 ± 1.16 0.1330 n.s. n.s. n.s.
Triol/TC 1.41 ± 0.5 1.29 ± 0.55 1.47 ± 0.58 0.6313 n.s. n.s. n.s.
25OH-CH 6.55 ± 1.55 6.69 ± 1.19 6.91 ± 1.55 0.3347 n.s. n.s. n.s.
25OH-CH/TC 3.32 ± 0.63 3.33 ± 0.51 3.34 ± 0.66 0.9324 n.s. n.s. n.s.
7bOH-CH 13.03 ± 10.57 11.98 ± 2.58 13.43 ± 4.61 0.1606 n.s. n.s. n.s.
7bOH-CH/TC 6.63 ± 4.87 5.96 ± 1.16 6.53 ± 2.12 0.8472 n.s. n.s. n.s.
4aOH-CH 5.38 ± 2.07 4.81 ± 1.09 5.80 ± 1.26 0.0019 n.s. 0.0023 0.0027
4aOH-CH/TC 2.74 ± 1.03 2.40 ± 0.49 2.82 ± 0.63 0.0866 n.s. n.s. n.s.
24OH-CH 45.51 ± 11.69 46.74 ± 11.74 46.78 ± 12.12 0.8184 n.s. n.s. n.s.
24OH-CH/TC 23.41 ± 6.54 23.13 ± 4.85 22.76 ± 5.92 0.8472 n.s. n.s. n.s.
7oxo-CH 12.79 ± 10.76 12.51 ± 3.06 13.03 ± 3.46 0.1195 n.s. n.s. n.s.
7oxo-CH/TC 6.56 ± 5.02 6.2 ± 1.35 6.34 ± 1.59 0.8472 n.s. n.s. n.s.
HC, healthy controls; MS, metabolic syndrome; OB, obesity; TC, total cholesterol; oxysterols (ng/mL); oxysterols/TC (ng/mg); n.s., not significant.
1 False Discovery Rate adjusted p-value of Kruskal–Wallis test.
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oxysterols, we show that only 4a-hydroxycholesterol was signifi-
cantly different between obesity and metabolic syndrome patients.
3.3. Influence of obesity and metabolic syndrome on the serum
oxysterol concentration in females
A completely different picture of oxysterols profile was
observed in females. Obese patients group showed lower levels
of 5,6a-epoxycholesterol, 4b-hydroxycholesterol and 24-hydroxy-
cholesterol, compared to healthy subjects (Table 3). Metabolic
syndrome group showed lower levels of 4b-hydroxysterol,
5,6a-epoxycholesterol, compared to healthy controls. Differently
from males, females carrying the features of metabolic syndrome
showed significantly higher concentrations of six oxysterols when
compared to healthy patients. Importantly the ratios between
oxysterols and cholesterol were also significantly different which
implies that changes in oxysterols were not just reflection of
changes in cholesterol levels. These oxysterols included 7a-hy-
droxycholesterol, 7b-hydroxycholesterol, 7-oxocholesterol, triol,
4a-hydroxycholesterol and 25-hydroxycholesterol. Amongst them,triol and 7b-hydroxycholesterol were significantly higher in
patients with metabolic syndrome when compared to obese
patients. However, the ratios between these oxysterol and choles-
terol were found not to be significantly different.3.4. Relationship between plasma fatty acids and oxysterols
The fatty acid profiles from healthy controls, obese patients and
patients with metabolic syndrome are reported in Supplementary
Tables 4 and 5. In the male population, we found little changes
in fatty acids whatever the clinical picture of the patients was con-
sidered. Adjusted p-values revealed that none of the fatty acids was
significantly related to the disease state (Supplementary Table 4).
In contrast, in females we identified significant changes in the fatty
acid profile of patients with obesity and metabolic syndrome
(Supplementary Table 5). In particular, compared to healthy con-
trols, obese patients showed higher levels of C18:0, C24:0,
C18:1n-7, C24:1n-9, C20:4n-6, C22:4n-6 and C22:5n-6, and lower
levels of C14:1, C18:2n-6 and C20:3n-3. The same picture was
observed in female patients with metabolic syndrome compared
Table 3
Concentration of serum cholesterol and oxysterols measured in females by health status.
HC OB MS p1 HC/OB HC/MS OB/MS
TC (mg/dL) 197.77 ± 37.46 178.21 ± 41.85 191.66 ± 38.69 0.1322 n.s. n.s. n.s.
4bOH-CH 21.99 ± 7.25 15.90 ± 5.77 16.20 ± 7.23 <0.0001 0.0008 <0.0001 n.s.
4bOH-CH/TC 11.28 ± 3.47 9.34 ± 4.32 8.48 ± 3.21 <0.0001 0.0061 <0.0001 n.s.
5aOH,6oxo-CH 1.05 ± 0.34 0.96 ± 0.24 1.04 ± 0.28 0.6250 n.s. n.s. n.s.
5aOH,6oxo-CH/TC 0.54 ± 0.15 0.55 ± 0.12 0.55 ± 0.14 0.7325 n.s. n.s. n.s.
5,6a-epoxy 7.57 ± 4.43 5.84 ± 3.23 5.25 ± 2.35 0.0003 0.017 <0.0001 n.s.
5,6a-epoxy/TC 3.87 ± 2.11 3.43 ± 1.92 2.78 ± 1.09 0.0033 n.s. 0.0010 n.s.
5,6b-epoxy 12.54 ± 5.37 10.93 ± 3.72 10.60 ± 3.26 0.1216 n.s. n.s. n.s.
5,6b-epoxy/TC 6.42 ± 2.50 6.46 ± 2.56 5.66 ± 1.85 0.2972 n.s. n.s. n.s.
27OH-CH 46.34 ± 11.45 42.71 ± 8.80 41.15 ± 10.78 0.0893 n.s. n.s. n.s.
27OH-CH/TC 24.08 ± 6.80 24.90 ± 6.09 21.88 ± 5.73 0.0946 n.s. n.s. n.s.
7aOH-CH 23.56 ± 13.66 23.03 ± 12.89 32.79 ± 18.69 0.0176 n.s. 0.014 n.s.
7aOH-CH/TC 11.71 ± 5.57 14.47 ± 13.06 17.18 ± 10.15 0.0054 n.s. 0.0029 n.s.
Triol 2.90 ± 1.09 2.88 ± 0.88 3.47 ± 0.76 0.0011 n.s. 0.0005 0.0097
Triol/TC 1.52 ± 0.66 1.70 ± 0.70 1.88 ± 0.56 0.0008 n.s. 0.0002 n.s.
25OH-CH 6.74 ± 1.24 6.82 ± 1.34 7.46 ± 1.32 0.0176 n.s. 0.013 n.s.
25OH-CH/TC 3.47 ± 0.61 3.97 ± 0.98 3.97 ± 0.69 0.0006 0.0168 0.0002 n.s.
4aOH-CH 4.90 ± 1.04 5.46 ± 2.30 5.53 ± 1.41 0.0448 n.s. 0.033 n.s.
4aOH-CH/TC 2.51 ± 0.43 3.18 ± 1.44 2.95 ± 0.83 0.0019 0.0106 0.0021 n.s.
7bOH-CH 13.18 ± 3.61 13.11 ± 2.23 15.93 ± 3.85 0.0003 n.s. <0.0001 0.0042
7bOH-CH/TC 6.79 ± 1.51 7.82 ± 2.62 8.48 ± 2.24 <0.0001 n.s. <0.0001 n.s.
24OH-CH 47.58 ± 11.16 39.23 ± 8.56 45.86 ± 14.89 0.0197 0.01 n.s. n.s.
24OH-CH/TC 24.71 ± 6.90 22.59 ± 4.84 23.99 ± 5.70 0.7395 n.s. n.s. n.s.
7oxo-CH 10.56 ± 3.25 10.26 ± 2.46 12.14 ± 3.58 0.0141 n.s. 0.012 n.s.
7oxo-CH/TC 5.39 ± 1.46 6.32 ± 3.50 6.51 ± 2.20 0.0022 n.s. 0.0005 n.s.
HC, healthy controls; MS, metabolic syndrome; OB, obesity; TC, total cholesterol; oxysterols (ng/mL); oxysterols/TC (ng/mg); n.s., not significant.
1 False Discovery Rate adjusted p-value of Kruskal–Wallis test.
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metabolic syndrome.
Next, we questioned whether individual measures of oxysterols
might correlate with some fatty acids. We identified significant
correlations between various oxysterols and fatty acids (Fig. 1).
Interestingly, 4b-hydroxysterol that is reduced in obesity and in
metabolic syndrome markedly correlated with a number of fatty
acids that are end-products of de novo lipogenesis (C14:0, C16:0,
C16:1n-7 and C18:1n-9) both in males and in females
(Supplementary Figs. 1 and 2). While some of these fatty acids
are part of the diet, ratios between products and substrates are
used as indicators of Stearoyl-CoA Desaturase activities. We calcu-
lated these ratios and found that consistent with the gender-speci-
fic effect on oxysterols there is also a marked gender-specific effect
of mono-unsaturated to saturated ratios (Supplementary Fig. 3).4. Discussion
Growing evidence indicates that obesity epidemic is associated
with increased prevalence of a number diseases – including liver,
reproductive system and autoimmune disorders as well as cancer
[4–8]. Many lipid molecular species have been implicated in the
etiology of obesity associated diseases. The best known examples
are fatty acids that may influence lipotoxicity in insulin-sensitive
tissues and play a part in the development of type II diabetes
[26–28].
Little is known about the possible role of oxysterols, a family of
highly bioactive lipids [23,29,30], in obesity and obesity-related
diseases. Experimental models provided evidence that oxysterols
control fatty acid homeostasis by acting as ligands for transcription
factors, i.e. LXRs, that regulate whole body lipid homeostasis
[14,17]. In the present study, we measured circulating oxysterols
and fatty acids in patients with obesity and metabolic syndrome,
healthy subjects serving as control, looking at differences and
potential correlation between the two lipid systems.Compared to healthy controls, we found gender-related distri-
bution of circulating oxysterols and fatty acids in patients with
obesity and metabolic syndrome. Concerning oxysterols levels in
male patients, we found significant changes in 4a- and 4b-hydrox-
ycholesterol levels only. Similar findings were observed in females
but, in addition, significant changes were observed in several oxys-
terols of both enzymatic and non-enzymatic origin. In particular,
higher levels of 7b-hydroxycholesterol and triol were found in
female patients with metabolic syndrome compared to healthy
controls or obese patients. These observations are consistent with
the well-known sexual dimorphism in lipid metabolism [31]. To
our knowledge, only 7-oxysterols were reported as possible mark-
ers of atherogenic dyslipidemia in adolescence [32]. Whether the
changes in oxysterols reported in males and in females might be
promoting diseases associated with obesity or with metabolic it
remains to be determined. However, the hypothesis that oxysterols
may be involved in sex-specific disease progression is worthy of
further investigation.
Similar to the oxysterol profiles, we found that the fatty acid
pattern was profoundly altered in female but not in male patients
with obesity and metabolic syndrome. Several components of the
saturated, monounsaturated and n-6 polyunsaturated FA were
found altered in the two disease groups compared to healthy con-
trols. The n-3 FA class did not show relevant changes apart from
C20:3n-3 that was reduced in both obesity and metabolic syn-
drome. Similarly to the Atherosclerosis Risk in Community (ARIC)
study [33], we found reduced levels of linoleic acid (C18:2n-6)
pointing to a potentially imbalanced dietary intake or to a defect
in the metabolism of essential fatty acids in female patients with
obesity and metabolic syndrome.
There has been a lot if interest in the role of palmitoleic acid
(C16:1n-7) as an endogenous lipid mediator [34]. Our data show
significantly higher levels of palmitoleic acid in female patients
with metabolic syndrome. These findings are in agreement with
the ARIC Study [33] but put into question the beneficial effects of
this potential lipokine in female. Since C16:1n-7 shows such a
Fig. 1. Hierarchical clustering of oxysterols and fatty acids concentration and heatmap of the correlation between oxysterol and fatty acid abundance in the whole
population. Heatmaps of Kendall correlation coefficients are based on a double hierarchical clustering (rows and columns of the correlation matrix are simultaneously
analyzed): rows and columns are both ordered according to the hierarchical clustering. The color of each section is proportional to the level of correlations (dark, high
correlation; bright, low correlation).
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ally dimorphic regulation of the key enzymes involved in palmi-
toleate metabolism [35]. To the best of our knowledge, little is
known about the gender-specific activity of D9-desaturase
(Stearoyl-CoA Desaturases) and Elongase (Elovl6) in lipogenic
human tissues such as the liver and the white adipose tissues.
Therefore, we calculated ratios between the abundance of mono-
unsaturated fatty acids of the n-7 and n-9 series and the abun-
dance of their respective saturated precursor. We found a signifi-
cant effect of obesity and metabolic syndrome on both ratios but
only in females, which is consistent with a gender-specific regula-
tion of lipogenesis. In addition, we found that both ratios behave
oppositely. While the n-9 ratio decreases, the n-7 ratio increases.
The n-7 ratio is a better indicator of D9-desaturas activity because
in the n-9 series, a lot of circulating C18:1n-9 may be provided
through the diet. The increase in n-7 ratio in obese and in patients
with metabolic syndrome may be indicative of increased lipogen-
esis and, possibly, non alcoholic fatty liver disease, which is highly
prevalent in patients with obesity and metabolic syndrome [36].
Finally, we identified statistically significant relationships
between circulating fatty acids and oxysterols. In human, this
observation is consistent with the evidence provided by pre-clini-
cal studies showing that the oxysterol receptor LXR drives de novo
lipogenic genes [14,17] and dietary fatty acids may impact on LXR
activity [18,19]. Interestingly, the most striking correlation
observed were those linking 4b-hydroxycholesterol to saturated
and mono-unsaturated fatty acids, both in males and females.
4b-hydroxycholesterol has a unusually long half-life in human
plasma due to slow 7a-hydroxylation required for its clearance
[37] and it is formed by the drug-metabolizing enzyme cyto-
chrome P450 3A4 [38]. It is therefore possible that lipogenic genes
and 4b-hydroxycholesterol degrading enzymes are co-regulated in
humans. Another possibility is that a regulator of lipogenesis orfatty acid(s) produced by de novo lipogenesis may inhibit Cyp3A4
expression and/or activity.
Altogether, we provide the first report showing the complete
picture of oxysterol and FA profile in patients with obesity and
metabolic syndrome. Data reported here support gender-specific
oxysterol profiles that should be taken into account in the analysis
and treatment of human diseases associated with obesity and
metabolic syndrome.
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